Why minimal is not optimal: Driving the mammalian cell cycle - and drug discovery - with a physiologic CDK control network

Cell Cycle

Volumn 11, Issue 14, 2012, Pages 2600-2605

  Merrick, Karl A ^a,b,c   Fisher, Robert P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Analog sensitive (AS) kinase; Cancer drug discovery; Cdk2; Cell cycle; Chemical genetics; Cyclin; Cyclin dependent kinase (CDK); DNA synthesis (S) phase; Restriction point

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P107; PROTEIN P130; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ALLELE; CATALYSIS; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); DNA DAMAGE; DNA REPLICATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; GENOTYPE; HUMAN; MAMMAL CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE;

EUKARYOTA; MAMMALIA; METAZOA;

EID: 84864390302     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20758     Document Type: Review

References (47)

1. Morgan DO. The Cell Cycle: Principles of Control. London: New Science Press Ltd. 2007.
2. Loog M, Morgan DO. Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates. Nature 2005; 434:104-8; PMID:15744308; http://dx.doi.org/10.1038/nature03329.
3. Kõivomägi M, Valk E, Venta R, Iofik A, Lepiku M, Morgan DO, et al. Dynamics of Cdk1 substrate specificity during the cell cycle. Mol Cell 2011; 42:610-23; PMID:21658602; http://dx.doi.org/10.1016/j.molcel.2011.05.016.
4. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell cycle control. Nat Rev Mol Cell Biol 2007; 8:149-60; PMID:17245415; http://dx.doi.org/10.1038/nrm2105.
5. Merrick KA, Fisher RP. Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle. Cell Cycle 2010; 9:706-14; PMID:20139727; http://dx.doi.org/10.4161/cc.9.4. 10732.
6. Merrick KA, Larochelle S, Zhang C, Allen JJ, Shokat KM, Fisher RP. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell 2008; 32:662-72; PMID:19061641; http://dx.doi.org/10. 1016/j.mol-cel.2008.10.022.
7. 1-to-S phase transition. Mol Cell Biol 1995; 15:2612-24; PMID:7739542.
8. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11:961-71; PMID:1312467.
9. 1-to-S transition in mammalian cells. Oncogene 1993; 8:1593-602; PMID:8502482.
10. Itzhaki JE, Gilbert CS, Porter AC. Construction by gene targeting in human cells of a "conditional'CDC2 mutant that rereplicates its DNA. Nat Genet 1997; 15:258-65; PMID:9054937; http://dx.doi.org/10.1038/ng0397-258.
11. Sigrist S, Ried G, Lehner CF. Dmcdc2 kinase is required for both meiotic divisions during Drosophila spermatogenesis and is activated by the Twine/cdc25 phosphatase. Mech Dev 1995; 53:247-60; PMID:8562426; http://dx.doi.org/10.1016/ 0925-4773(95)00441-3.
12. Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 1998; 12:370-81; PMID:9450931; http://dx.doi.org/10.1101/gad.12.3.370.
13. Hochegger H, Dejsuphong D, Sonoda E, Saberi A, Rajendra E, Kirk J, et al. An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J Cell Biol 2007; 178:257-68; PMID:17635936; http://dx.doi.org/10.1083/jcb.200702034.
14. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262:2050-4; PMID:8266103; http://dx.doi.org/10.1126/science.8266103.
15. Hu B, Mitra J, van den Heuvel S, Enders GH. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001; 21:2755-66; PMID:11283255; http://dx.doi.org/10.1128/MCB.21. 8.2755-66.2001.
16. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45; PMID:12676582; http://dx.doi.org/10. 1016/S1535-6108(03)00053-9.
17. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13:1775-85; PMID:14561402; http://dx.doi.org/10. 1016/j.cub.2003.09.024.
18. Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31; PMID:12923533; http://dx.doi.org/10. 1038/ng1232.
19. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22:44-52; PMID:10319860; http://dx.doi.org/10.1038/8751.
20. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999; 19:7011-9; PMID:10490638.
21. Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118:493-504; PMID:15315761; http://dx.doi.org/10.1016/j.cell.2004.08.002.
22. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448:811-5; PMID:17700700; http://dx.doi.org/10.1038/nature06046.
23. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006; 10:563-73; PMID:16678773; http://dx.doi.org/10.1016/j.devcel.2006.03.004.
24. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118:477-91; PMID:15315760; http://dx.doi.org/10.1016/j.cell.2004.07. 025.
25. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 1999; 97:767-77; PMID:10380928; http://dx.doi.org/10.1016/S0092-8674(00)80788-6.
26. 1/S phase transition. Nat Cell Biol 2005; 7:831-6; PMID:16007079; http://dx.doi.org/10.1038/ncb1284.
27. Desai D, Wessling HC, Fisher RP, Morgan DO. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol 1995; 15:345-50; PMID:7799941.
28. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10. 1038/nrc2602.
29. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 2007; 25:839-50; PMID:17386261; http://dx.doi.org/10.1016/j.molcel.2007.02.003.
30. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994; 78:713-24; PMID:8069918; http://dx.doi.org/10.1016/0092-8674(94)90535-5.
31. Mäkelä TP, Tassan JP, Nigg EA, Frutiger S, Hughes GJ, Weinberg RA. A cyclin associated with the CDK-activating kinase MO15. Nature 1994; 371:254-7; PMID:8078587; http://dx.doi.org/10.1038/371254a0.
32. Merrick KA, Wohlbold L, Zhang C, Allen JJ, Horiuchi D, Huskey NE, et al. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell 2011; 42:624-36; PMID:21658603; http://dx.doi.org/10.1016/j.mol-cel.2011.03.031.
33. Katsuno Y, Suzuki A, Sugimura K, Okumura K, Zineldeen DH, Shimada M, et al. Cyclin A-Cdk1 regulates the origin firing program in mammalian cells. Proc Natl Acad Sci USA 2009; 106:3184-9; PMID:19221029; http://dx.doi.org/10.1073/ pnas.0809350106.
34. Koseoglu MM, Graves LM, Marzluff WF. Phosphorylation of threonine 61 by cyclin a/Cdk1 triggers degradation of stem-loop binding protein at the end of S phase. Mol Cell Biol 2008; 28:4469-79; PMID:18490441; http://dx.doi.org/10.1128/ MCB.01416-07.
35. Eser U, Falleur-Fettig M, Johnson A, Skotheim JM. Commitment to a cellular transition precedes genome-wide transcriptional change. Mol Cell 2011; 43:515-27; PMID:21855792; http://dx.doi.org/10.1016/j.molcel.2011.06.024.
36. Skotheim JM, Di Talia S, Siggia ED, Cross FR. Positive feedback of G1 cyclins ensures coherent cell cycle entry. Nature 2008; 454:291-6; PMID:18633409; http://dx.doi.org/10.1038/nature07118.
37. 1-specific transcription via phosphorylation of the SBF bound repressor Whi5. Cell 2004; 117:887-98; PMID:15210110; http://dx.doi.org/10.1016/j.cell.2004.05.025.
38. 1/S transcription in yeast. Cell 2004; 117:899-913; PMID:15210111; http://dx.doi.org/10.1016/j. cell.2004.05.024.
39. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-31; PMID:11902577; http://dx.doi.org/10. 1038/35106065.
40. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9:785-97; PMID:19851314; http://dx.doi.org/10.1038/nrc2696.
41. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714-24; PMID:19143056; http://dx.doi.org/10.1038/nrc2401.
42. + breast cancer patients. Proc Natl Acad Sci USA 2011; 108:3761-6; PMID:21321214; http://dx.doi.org/10.1073/pnas. 1014835108.
43. Horiuchi D, E Huskey N, Kusdra L, Wohlbold L, Merrick KA, Zhang C, et al. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci USA 2012; 109:1019-27; PMID:22474407; http://dx.doi.org/10.1073/ pnas.1111317109.
44. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010; 14:1199-212; PMID:20932174; http://dx.doi.org/10.1517/14728222.2010.525221.
45. Ali A, Ghosh A, Nathans RS, Sharova N, O'Brien S, Cao H, et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem 2009; 10:2072-80; PMID:19603446; http://dx.doi.org/10.1002/cbic. 200900303.
46. Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 2009; 69:6208-15; PMID:19638587; http://dx.doi.org/10.1158/0008-5472.CAN-09-0301.
47. Koseoglu MM, Dong J, Marzluff WF. Coordinate regulation of histone mRNA metabolism and DNA replication: cyclin A/cdk1 is involved in inactivation of histone mRNA metabolism and DNA replication at the end of S phase. Cell Cycle 2010; 9:3857-63; PMID:20935461; http://dx.doi.org/10.4161/cc.9.19.13300.